Clinical trial
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
NCT00030095 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00030095 |
|---|---|
| Title | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Trial Of 2-Methoxyestradiol (2ME2), (NSC-659853) An Angiogenesis Inhibitor, In Patients With Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | 2-methoxyestradiol |
| Start date | Sep 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: